000739:SHE
Apeloa Pharmaceutical Co Ltd
23,42 CNY
arrow_downward
−1,64%(−0,39) 1D
16. lis, 15:04:48 GMT+8 · CNY
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 000739...
Otvori
24,04 CNY
Najviša
24,76 CNY
Najniža
23,09 CNY
Trž. kap.
27,13 mlr.
Prosj. kol.
16,27 mil.
Količina
15,09 mil.
Dividenda
1,61 %
Kvartalna dividenda
0,09 CNY
Datum nakon isplate dividende
8. lis 2026.
P/E omjer
31,78
52-tjed. najviša
28,50 CNY
52-tjed. najniža
14,89 CNY
EPS
0,74 CNY
Dionice u optjecaju
1,16 mlr.
Broj djelatnika
7 tis.
Otvori
24,04 CNY
Najviša
24,76 CNY
Najniža
23,09 CNY
Trž. kap.
27,13 mlr.
Prosj. kol.
16,27 mil.
Količina
15,09 mil.
Dividenda
1,61 %
Kvartalna dividenda
0,09 CNY
Datum nakon isplate dividende
8. lis 2026.
P/E omjer
31,78
52-tjed. najviša
28,50 CNY
52-tjed. najniža
14,89 CNY
EPS
0,74 CNY
Dionice u optjecaju
1,16 mlr.
Broj djelatnika
7 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Financije.hr
·
prije 1 dan
Wall Street pred otvaranjem: Rotacija iz tehnologije jača, Dow preuzima vodstvo
Yahoo Finance
·
prije 3 sata
Michael Burry Warns of a Stock Market ‘Supervolcano’
Simply Wall Street
·
prije 18 minuta
Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?
MarketWatch
·
prije 32 minute
Opinion: There is a silent market rotation inside the S&P 500 that’s warning of more weakness ahead
Profil
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
Apeloa Pharmaceutical Co Ltd – informacije